相关实验视频

Updated: Oct 26, 2025

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

药物诱导的脂症混了SARS-CoV-2的药物重用

Tia A Tummino^1,2,3,4, Veronica V Rezelj⁵, Benoit Fischer⁶

¹Department of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, CA, USA.

Science (New York, N.Y.)

|July 30, 2021

概括

许多重新使用的COVID-19药物会引起脂症,这种疾病与它们的抗病毒作用有关. 这种有毒的副作用,而不是针对特定目标的活性,可能会误导SARS-CoV-2治疗的药物发现工作.

科学领域:

药物重新使用
病毒学
毒理学

背景情况:

用于COVID-19治疗的药物转化是一个重要的研究领域.
最初的研究表明,包括西格玛受体配体在内的各种药物对抗SARS-CoV-2具有前景.
需要对潜在的共享机制进行研究.

研究的目的:

研究脂症作为抗病毒活性机制在COVID-19重定向药物中的作用.
要确定脂症是否是治疗潜力的可靠指标或混的毒性作用.

主要方法:

针对SARS-CoV-2的抗病毒活性选23种阴性两性药物.
脂诱导与抗病毒功效之间的相关性分析.
诱导脂症的药物与不诱导脂症的药物进行比较,但针对相同的途径.

主要成果:

对于所有23种测试的化两性药物,观察到脂和抗病毒功效之间的单调相关性.
尽管针对相同的途径,但没有诱导脂症的药物缺乏抗病毒活性.
发现脂症取决于药物的物理化学性质,而不是特定的位.

结论:

脂症是一种与许多针对SARS-CoV-2的抗病毒药物的有效性相关的共享机制.
这种现象代表了早期药物发现的毒性混,
早期检测脂症至关重要,以避免人工物并专注于真正有效的COVID-19候选药物.

更多相关视频

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...